OCS PRESS-RELEASE SEC Filing Analysis

Latest settled — T+5d

OCS ▲ +2.73% at T+5d

NEUTRAL call ✓ call won +2.73% · α vs SPY +2.29% · entry $11.00 → $11.30

Next anchor: T+20d in 19d

Last close $11.22 (close Jun 18) · +2.00% from $11.00 entry

Entry anchored
Jun 10, 03:59 PM ET
via Databento tick

T+1d

+0.82%

call +0.82% · α +0.28%

$11.09

settled 9d ago

T+5d

+2.73%

call +2.73% · α +2.29%

$11.30

settled 3d ago

T+20d

—

call — · α —

—

in 19d

T+60d

—

call — · α —

—

in 3mo

Price Chart

Loading chart...

Executive Summary

Oculis announced a presentation at Clinical Trials at the Summit 2026 on its lead candidate Privosegtor, a peptoid small molecule for optic neuritis. The presentation covers the PIONEER registrational program, which follows positive Phase 2 ACUITY data and Breakthrough Therapy/PRIME designations. This is a routine pipeline update with no new clinical data or regulatory decision, making it a low-impact event.

Actionable Insight

This is a routine conference presentation with no new data or catalysts. Monitor for PIONEER-1 trial enrollment updates or future data readouts for material stock-moving events.

Key Facts

Presentation at Clinical Trials at the Summit 2026 on June 13, 2026, by CEO Riad Sherif.
Privosegtor has Breakthrough Therapy designation from FDA and PRIME designation from EMA for optic neuritis.
PIONEER registrational program includes two trials in optic neuritis and one in NAION.
No new clinical data or regulatory milestones announced in this press release.

Financial Impact

No financial data disclosed; routine pipeline update.

Risk Factors

Clinical trial failure or regulatory setback for Privosegtor.
Competition from other neuroprotective therapies in development.
Dependence on single lead candidate for near-term value.

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Analyst Consensus

94% bullish (16 analysts)

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3310224

10 reports for OCS

T+1T+5T+20T+60

100% Hit rate 3 of 3 directional calls best @ T+5▲ +50.63%May 29, 2026

Filters

Reports for OCS — sortable, filterable
	Type				Now
Jun 11, 2026 9d ago	Press Release NEUTRAL ★ 3/10	$11.00 $11.30	▲ +2.73%	▲ +2.29%	$11.22 (+2.00%)
Jun 9, 2026 11d ago	Press Release NEUTRAL ★ 5/10	$10.98 $11.61	▲ +5.74%	▲ +3.33%	$11.22 (+2.19%)
May 29, 2026 22d ago	Press Release BEARISH ★ 7/10	$22.71 $11.21	▲ +50.63%	▲ +48.10%	$11.22 (+50.58%)
May 11, 2026 5w ago	Press Release NEUTRAL ★ 5/10	$30.41 $28.07	▼ −7.69%	▼ −7.77%	$11.22 (−63.10%)
May 11, 2026 5w ago	Press Release NEUTRAL ★ 5/10	$30.41 $28.07	▼ −7.69%	▼ −7.77%	$11.22 (−63.10%)
May 7, 2026 6w ago	Press Release BULLISH ★ 7/10	$31.09 $31.37	▲ +0.90%	▼ −0.60%	$11.22 (−63.91%)
May 5, 2026 6w ago	Press Release NEUTRAL ★ 5/10	$27.75 $30.41	▲ +9.59%	▲ +7.60%	$11.22 (−59.57%)
Apr 20, 2026 8w ago	Press Release MIXED ★ 6/10	$28.61 $27.12	▼ −5.21%	▼ −6.12%	$11.22 (−60.78%)
Mar 16, 2026 13w ago	Press Release BULLISH ★ 8/10	$26.02 $24.60	▼ −5.46%	▼ −3.42%	$11.22 (−56.88%)
Mar 3, 2026 15w ago	Press Release MIXED ★ 7/10	$27.72 $27.28	▼ −1.59%	▼ −0.25%	$11.22 (−59.52%)

US Market Status

Market Closed — Opens Mon (29h 34m)

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access